Humanized anti-GD2 antibody

Phase 2Biologic

MMemorial Sloan Kettering Cancer Center

Humanized anti-GD2 antibody is one of 2 biologic programs targeting Recurrent Osteosarcoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recurrent OsteosarcomaActive, not recruiting

Recurrent OsteosarcomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Recurrent Osteosarcoma

#DrugCompanyPhaseTrials

GM-CSF

YY-mAbs Therapeutics

Phase 2

1 2

Humanized anti-GD2 antibody

MMemorial Sloan Kettering Cancer Center

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Recurrent Osteosarcoma

NCT02502786

Clinical

Trials by Indication[1]

Neuroblastoma1 trial

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT01576692·34 enrolled

Recurrent Osteosarcoma1 trial

A Phase II Study of Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT02502786·46 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Humanized anti-GD2 antibody. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Humanized anti-GD2 antibody compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Humanized anti-GD2 antibody. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Memorial Sloan Kettering Cancer Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: MMemorial Sloan Kettering Cancer Center

Humanized anti-GD2 antibody

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Neuroblastoma1 trial

Recurrent Osteosarcoma1 trial

References

Drug Info

Quick Facts

Related News